Cancer News and Research

Latest Cancer News and Research

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.

22 Jul 2010

BSD provides additional information to FDA for 510(k) submission of MicroThermX Microwave Ablation System

BSD Medical Corporation today announced that it has provided the additional information requested by the U.S. Food and Drug Administration (FDA) for review of the 510(k) submission the Company filed for premarket clearance of the Company's Phase II MicroThermX® Microwave Ablation System (MTX-180) for ablation of soft tissue.

22 Jul 2010

Researchers receive $780,000 to study estrogen levels, behavior of breast cancer tumors

Researchers at the University of California, San Diego School of Medicine received nearly $780,000 from the Susan G. Komen for the Cure for two studies regarding estrogen levels and the behavior of breast cancer tumors.

22 Jul 2010

New campaign empowers, inspires women and families affected by epilepsy

A new campaign explores the roles and responsibilities women uniquely encounter when living, or caring for a loved one, with epilepsy. "Women Succeeding with Epilepsy" is a collaboration between Epilepsy Advocate and HealthyWomen to educate, empower and inspire women and families whose lives are affected by epilepsy.

22 Jul 2010

SAIC-F selects SAIC-F selects Precision Antibody to provide characterization for reference antibody resource development

Precision Antibody announced today its selection by Science Applications International Corporation-Frederick to provide antibody and antigen characterization, including surface plasmon resonance analysis, for the National Cancer Institute's "Clinical Proteomic Technologies for Cancer" initiative. A goal of the CPTC is to develop a standardized resource of very high-quality, renewable reference antibodies generated against cancer-related proteins. The antibodies will be made available to proteomics researchers, along with characterization data and other information intended to support replication and standardization.

22 Jul 2010

Researchers speculate about risks, rewards of making clinicians' notes transparent to patients

Technology has placed vast amounts of medical information literally a mouse click away. Yet what often may be central - a doctor's notes about a patient visit - has traditionally not been part of the discussion. In effect, such records have long been out of bounds.

22 Jul 2010

Survey links autism with digestive problems, intestinal inflammation

Autism is the fastest growing developmental disorder in the world. With 1 child in 91 facing the disorder, the diagnosis is more common than pediatric cancer, diabetes, and AIDS combined.

22 Jul 2010

Womb cancer is the fourth most common cancer among UK women: Research

Womb cancer cases are highest ever for over three decades.The number of women diagnosed with womb cancer is at its highest for over 30 years according to new figures published today by Cancer Research UK which show more than 7,530 people now develop the disease each year in the UK.

22 Jul 2010

Affymetrix second-quarter total revenue decreases to $71.7 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2010. Total revenue for the quarter was $71.7 million, in line with previously announced expectations, as compared to total revenue of $81.6 million in the second quarter of 2009.

22 Jul 2010

Buffer among metbolism pathways induces cancer suppressing gene mutation: Research

Eighty years ago, the medical establishment believed cancer was caused by a dysfunction of metabolism, but the idea went out of vogue. Now, scientists are again looking at metabolism and its role in cancer and other common diseases. Metabolism is a highly connected network of reactions that are arranged in parallel and interacting pathways. Such parallelism can mask how genes are linked with disease traits and make it difficult to treat conditions.

22 Jul 2010

CFAR receives a five-year renewal grant to continue AIDS research

The Case Western Reserve University/University Hospitals Case Medical Center Center for AIDS Research announced today it has received a five-year renewal grant from the National Institutes of Health for $9 million. The CFAR provides clinical and technological support to researchers working on HIV-related projects at Case Western Reserve, University Hospital Case Medical Center, MetroHealth Medical Center, Cleveland Clinic, and several international sites.

22 Jul 2010

Avastin – breast cancer drug, fails to pass the FDA advisory panel vote on efficacy

According to a Food and Drug Administration (FDA) advisory committee’s (The Oncology Drugs Advisory Committee, or ODAC) recommendation this Tuesday, the marketing approval of the popular breast cancer drug, Avastin or Bevacizumab should be withdrawn.

21 Jul 2010

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme Corp. today reported that second-quarter revenue was $1.08 billion, compared with $1.23 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints in 2010. The company expects to be able to increase shipments of Cerezyme and Fabrazyme during the second half of the year.

21 Jul 2010

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

AMRI has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity. The announcement was made yesterday during a presentation by AMRI's Dr. Peter Guzzo, director, discovery research and development, at the 6th Obesity and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported.

21 Jul 2010

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.

21 Jul 2010

Report: Older gay, bisexual men enrolled in long-term study of HIV used illicit drugs infrequently

Most older gay and bisexual men enrolled in a long-term study of HIV used recreational drugs infrequently over a 10-year period, report University of Pittsburgh Graduate School of Public Health researchers at the XVIII International AIDS Conference.

21 Jul 2010

Genmab reports Arzerra net sales of DKK 73 million during second-quarter 2010

Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.

21 Jul 2010

Researchers develop new way to reduce radiation dose in CT perfusion procedure

Perfusion CT scanning, an emerging imaging technology, got a bad rap last year when a machine set to incorrect radiation levels overdosed hundreds of people in Los Angeles. In the wake of this incident, researchers at the Mayo Clinic, excited by the technology's promise for diagnosing stroke, cancer, and possibly heart disease, have developed a way to reduce the amount of radiation involved in the procedure -- which, when done properly, already involves very little risk.

21 Jul 2010

Researchers find that increase in leptin may promote colorectal neoplasms

Now, for the first time, a collaborative study of researchers at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology and the Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy have found that an increase in leptin, a cytokine that is normally increased in obese or overweight individuals, may promote colorectal neoplasms by activating colorectal cancer stem cells.

21 Jul 2010

Abbott second-quarter global sales increase 17.8% to $8.8 billion

Abbott today announced financial results for the second quarter ended June 30, 2010.

21 Jul 2010

Cancer News and Research

Latest Cancer News and Research

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

BSD provides additional information to FDA for 510(k) submission of MicroThermX Microwave Ablation System

Researchers receive $780,000 to study estrogen levels, behavior of breast cancer tumors

New campaign empowers, inspires women and families affected by epilepsy

SAIC-F selects SAIC-F selects Precision Antibody to provide characterization for reference antibody resource development

Researchers speculate about risks, rewards of making clinicians' notes transparent to patients

Survey links autism with digestive problems, intestinal inflammation

Womb cancer is the fourth most common cancer among UK women: Research

Affymetrix second-quarter total revenue decreases to $71.7 million

Buffer among metbolism pathways induces cancer suppressing gene mutation: Research

CFAR receives a five-year renewal grant to continue AIDS research

Avastin – breast cancer drug, fails to pass the FDA advisory panel vote on efficacy

Genzyme second-quarter revenue decreases to $1.08 billion

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Report: Older gay, bisexual men enrolled in long-term study of HIV used illicit drugs infrequently

Genmab reports Arzerra net sales of DKK 73 million during second-quarter 2010

Researchers develop new way to reduce radiation dose in CT perfusion procedure

Researchers find that increase in leptin may promote colorectal neoplasms

Abbott second-quarter global sales increase 17.8% to $8.8 billion

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in